Presentation at plenary session on clinical trials will highlight initial clinical data from ongoing ADCElerate1 trial in patients with advanced soft tissue sarcoma
Copenhagen, Denmark, November 10, 2026 – Adcendo ApS (“Adcendo”), a biotech company focused on developing a pipeline of differentiated antibody-drug conjugates (ADCs) for cancers with high unmet medical need, today announced a late-breaking oral presentation highlighting initial clinical data from the ongoing Phase 1 ADCElerate1 trial evaluating ADCE-D01, a first-in-class ADC against the novel target uPARAP, in patients with advanced soft tissue sarcoma, at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), taking place November 18-20, 2026, in Barcelona, Spain.
Oral Presentation Details:
Title: A novel antibody-drug conjugate targeting urokinase plasminogen activator receptor-associated protein in previously treated patients with advanced soft tissue sarcoma: emerging clinical results from the phase 1 ADCElerate1 study (NCT06797999)
Presenter: Dr. Patrick Schöffski, University Hospitals Leuven and KU Leuven, Belgium
Session: Plenary Session 3 – Proffered Papers: Clinical Trials
Abstract number: 4LBA
Date and time: Thursday, November 19, 2026, at 10:00 a.m. CET / 4:00 a.m. ET
About Adcendo ApS
Adcendo ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts. The company is developing a pipeline of differentiated antibody-drug conjugates (ADCs) for cancers with high unmet medical need using a disease- and target-driven approach, focused on balancing efficacy and tolerability. Led by a team of experienced biopharma executives with a track record of advancing multiple ADCs to approval, Adcendo integrates deep ADC expertise into target and disease biology, with research, clinical and commercial insight to drive next-generation cancer therapies. Adcendo is currently advancing three clinical-stage ADC programs in indications of high unmet need, such as soft tissue sarcoma, squamous cell cancers, pancreatic ductal adenocarcinoma, and other solid tumors. For further information, please visit https://adcendo.com/ or follow us on LinkedIn.
CONTACT:
For further information:
Argot Partners
Tel: +1 (212) 600-1494
E-mail: adcendo@argotpartners.com
Adcendo ApS
Michael Pehl, CEO
Email: info@adcendo.com